We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
-1.2%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$212M
(-28%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-25.42%
Top 10 Holdings %
Top 10 Hldgs %
37.58%
Holding
232
New
36
Increased
20
Reduced
48
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESPR
Esperion Therapeutics
ESPR
|
+$11.6M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$8.51M |
| 3 |
United Therapeutics
UTHR
|
+$8.13M |
| 4 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$5.75M |
| 5 |
Altimmune
ALT
|
+$5.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
+$21M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$9.33M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$8.38M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$7.11M |
| 5 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$6.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.2% |
| 2 | Technology | 0.14% |
| 3 | Consumer Staples | 0.03% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
CALL
Arcus Biosciences
RCUS
$3.33B
| $588K | 0.11% |
23,200
-126,800
| -85% | -$3.11M |
|
|
INBX
102
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $561K | 0.1% |
49,372
-108,470
| -69% | -$1.6M |
|
|
SYBX
103
DELISTED
Synlogic
SYBX
| $545K | 0.1% |
31,624
-3,028
| -9% | -$65.5K |
|
104
Evolus
EOLS
$397M
| $529K | 0.1% |
+45,516
| New | +$537K |
|
|
OKUR
105
OnKure Therapeutics
OKUR
$160M
| $491K | 0.09% |
18,560
| – | – |
|
|
ISEE
106
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $473K | 0.09% |
49,099
| – | – |
|
|
CASI
107
DELISTED
CASI Pharmaceuticals
CASI
| $378K | 0.07% |
132,014
-2
| -0% | -$9 |
|
108
NextCure
NXTC
$20.4M
| $336K | 0.06% |
5,953
-5,802
| -49% | -$303K |
|
109
Wave Life Sciences
WVE
$1.12B
| $318K | 0.06% |
98,039
-950,000
| -91% | -$1.83M |
|
110
Zai Lab
ZLAB
$2.07B
| $278K | 0.05% |
81,843
| – | – |
|
111
Verastem
VSTM
$528M
| $265K | 0.05% |
19,002
-37,500
| -66% | -$597K |
|
112
CALL
Praxis Precision Medicines
PRAX
$8.11B
| $263K | 0.05% |
+7,147
| New | +$763K |
|
|
HYFT
113
MindWalk Holdings
HYFT
$60.7M
| $237K | 0.04% |
61,433
-16,217
| -21% | -$81.9K |
|
|
HEPA
114
DELISTED
Hepion Pharmaceuticals
HEPA
| $235K | 0.04% |
410
-172
| -30% | -$143K |
|
115
Biogen
BIIB
$30.9B
| $228K | 0.04% |
1,122
| – | – |
|
116
Corbus Pharmaceuticals
CRBP
$165M
| $217K | 0.04% |
28,751
-4,503
| -14% | -$43.5K |
|
|
RGLS
117
DELISTED
Regulus Therapeutics
RGLS
| $217K | 0.04% |
105,341
-23,572
| -18% | -$57.2K |
|
118
Immunic
IMUX
$178M
| $214K | 0.04% |
+6,150
| New | +$394K |
|
|
119
PUT
Immunic
IMUX
$178M
| $213K | 0.04% |
6,150
| – | – |
|
|
VRNA
120
DELISTED
Verona Pharma
VRNA
| $200K | 0.04% |
+300,000
| New | +$1.28M |
|
|
MREO
121
Mereo BioPharma
MREO
$48.9M
| $199K | 0.04% |
615,856
-300,000
| -33% | -$232K |
|
|
KA
122
DELISTED
Kineta, Inc. Common Stock
KA
| $190K | 0.03% |
14,913
-18,842
| -56% | -$181K |
|
|
ASLN
123
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $185K | 0.03% |
24,269
| – | – |
|
124
Clene
CLNN
$60.3M
| $177K | 0.03% |
3,500
-22,214
| -86% | -$1.24M |
|
|
QCLS
125
Q/C Technologies Inc
QCLS
$19.7M
| $176K | 0.03% |
27
-17
| -39% | -$156K |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q2 2022 Portfolio in Review
As of Q2 2022, Ikarian Capital held 232 positions worth $548M, down 28% from $760M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Ikarian Capital withdrew a net $139M in Q2 2022, closing 92 positions and reducing 48 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Ikarian Capital opened a new position in Esperion Therapeutics worth $13.1M.
- Ikarian Capital's largest Q2 2022 buy was Esperion Therapeutics: 2,054,602 shares worth $13.1M.
- Ikarian Capital added most to Alnylam Pharmaceuticals in Q2 2022, an estimated $8.51M increase.
- Ikarian Capital's biggest Q2 2022 reduction was Adicet Bio, cutting an estimated $5M.
- Ikarian Capital fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $21M.
- Ikarian Capital's ten largest holdings make up 38% of its $548M portfolio in Q2 2022.
- Ikarian Capital opened 36 new positions and closed 92 in Q2 2022.
- Ikarian Capital's portfolio value fell 28% quarter-over-quarter to $548M.
Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.